Oncotelic Therapeutics, Inc.
OTLC
$0.056
-$0.0024-4.11%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 134.11% | -59.67% | -15.89% | -70.58% | -94.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.59% | -59.55% | -36.69% | -72.62% | -90.68% |
| Operating Income | -657.24% | 59.55% | 36.69% | 72.62% | 102.44% |
| Income Before Tax | -8,303.65% | 95.94% | 21.58% | 85.20% | 104.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8,303.65% | 95.94% | 21.58% | 85.20% | 104.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -9.43% | -26.56% | -17.49% | 0.36% | -8.96% |
| Net Income | -2,966.00% | 96.90% | 22.21% | 86.09% | 114.82% |
| EBIT | -657.24% | 59.55% | 36.69% | 72.62% | 102.44% |
| EBITDA | -- | -- | -- | 73.40% | 102.97% |
| EPS Basic | -2,800.00% | 97.08% | 23.08% | 87.05% | 115.00% |
| Normalized Basic EPS | -125.00% | 70.00% | 50.00% | 63.16% | 133.33% |
| EPS Diluted | -3,433.33% | 97.08% | 23.08% | 87.05% | 115.00% |
| Normalized Diluted EPS | -125.00% | 70.00% | 50.00% | 63.16% | 133.33% |
| Average Basic Shares Outstanding | 2.39% | 1.83% | 1.79% | 5.13% | 2.85% |
| Average Diluted Shares Outstanding | 2.39% | 1.83% | 1.79% | 5.13% | 2.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |